Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency chief counsel says exclusivity for better formulations may need to be considered.


Related Content

Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst